LONDON, ENGLAND / ACCESSWIRE / May 6, 2015 / Today, True Leaf Medicine International Ltd. (CSE: MJ; TLA.F; WKN: A14NM1) announced to have exclusively secured production capacities from existing pet food manufacturer, Wodema Industries Ltd. Additionally, True Leaf owns the 'right of first refusal' to acquire all production facilities from Kelowna, BC-based Wodema.
On April 9, we reported on True Leaf's plans to enter the pet food industry in fall 2015 with a hemp-based pet product line. Less than a month later, True Leaf surprises positively with this potential 'company-making' transaction, as it is now getting down to business to enter this $53 billion market.
The success story of Naturally Splendid Enterprises Ltd. has shown how lucrative it can be to enter the hemp-based pet food market (its stock rose 5-fold within few weeks and enjoys a market capitalization of $32 million CAD). True Leaf, with its 38 million shares in the market, has a current market valuation of $3 million CAD only. For such reasons, Rockstone Research will publish a detailed initiating coverage on True Leaf and the market for hemp and cannabis in Canada and USA shortly; as it became tangible today that the company has best chances for success.
The clou of today's press release: True Leaf does not need to handle a multi-mullion-dollar transaction to take over an existing producer. It is likely that the company will initially take over production capacities from Wodema and - as and when required (probably after the launch of its new product line) - will acquire Wodema's production facilities.
True Leaf's CEO, Darcy Bomford, has 30 years experience in the pet food business, which probably made today`s transaction possible. Another high-carat personality in True Leaf's team is chairman Michael Harcourt, former premier of British Columbia and mayor of Vancouver.
The rest of the article can be read with the following link:
Disclaimer: The author, Stephan Bogner (Dipl. Kfm., FH), owns shares of True Leaf Medicine International Ltd. and thus would profit from a share price appreciation, whereas the author may sell those any time without notice. Neither Rockstone Research nor the author was remunerated or instructed by True Leaf Medicine International Ltd. to produce or publish this content. However, please read the full disclaimer on www.rockstone-research.com as a conflict of interest exists with Zimtu Capital Corp. and none of this content is to be construed as a "financial analysis" or "investment advice".
SOURCE: Rockstone Research Ltd.
